Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $124,397.13 in Stock

Key Points

• Ross Moat, an insider at Kiniksa Pharmaceuticals, sold 3,523 shares of the company's stock for a total of $124,397.13, reducing his ownership by 27.23%.
• Kiniksa Pharmaceuticals reported $0.23 earnings per share (EPS) for the last quarter, beating analysts' estimates, and had revenues of $156.80 million.
• Analysts have set a new target price for Kiniksa Pharmaceuticals, with recommendations ranging from $36.00 to $54.00, indicating a generally positive outlook on the stock.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider Ross Moat sold 3,523 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the transaction, the insider owned 9,415 shares in the company, valued at approximately $332,443.65. This represents a 27.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded up $0.86 during mid-day trading on Monday, hitting $36.57. 549,446 shares of the company traded hands, compared to its average volume of 671,153. The stock has a 50-day moving average price of $30.95 and a two-hundred day moving average price of $26.59. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $36.74. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of 914.48 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on KNSA shares. Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, Kiniksa Pharmaceuticals International currently has an average rating of "Buy" and an average target price of $41.17.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock valued at $108,184,000 after acquiring an additional 526,567 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock worth $35,067,000 after purchasing an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.